CRISPR-based point-of-care diagnostics for viral hepatitis: from molecular design to clinical implementation
Frontiers in Bioengineering and Biotechnology·
- DOI
- 10.3389/fbioe.2026.1892898
- PMID
- —
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Frontiers Media SA
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Faster pathogen identification could facilitate earlier therapeutic interventions and strengthen broader elimination campaigns. Decentralized testing formats offer potential to reduce specimen transit times and improve patient retention throughout diagnostic sequences.
Structured evidence summary
Research question
The authors investigate how CRISPR-Cas molecular architectures can be matched to clinical and public health objectives for identifying hepatitis A through E infections. The work evaluates which technical parameters best overcome existing diagnostic bottlenecks.
Study design
This manuscript operates as a narrative review synthesizing existing literature on CRISPR-based detection methods for five hepatitis pathogens. It compares assay components and validation statuses without introducing original experimental datasets.
Population and setting
The discussion centers on healthcare environments where centralized laboratory networks cause logistical delays, particularly in resource-constrained regions. It addresses general viral hepatitis populations rather than a narrowly defined patient group.
Main findings
Validation data currently demonstrates greater maturity for hepatitis B and C detection compared to other strains. Diagnostic applications for hepatitis A, D, and E remain underdeveloped and heavily reliant on local operational contexts. Effective future platforms must incorporate stable reagents, closed-tube processing, and comprehensive genotype screening.
Public-health relevance
Faster pathogen identification could facilitate earlier therapeutic interventions and strengthen broader elimination campaigns. Decentralized testing formats offer potential to reduce specimen transit times and improve patient retention throughout diagnostic sequences.
Important limitations
The authors note that analytical sensitivity metrics alone are insufficient for determining real-world utility. Several viral targets lack robust clinical validation, and standardized economic evaluations alongside non-specialist usability testing are still pending.
GIDS interpretation
This publication maps the developmental stage of emerging nucleic acid detection tools against established diagnostic requirements for liver inflammation pathogens. It offers a comparative framework to guide subsequent research funding and technology translation efforts.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.